Olumide Ibrahim Anifowoshe, MD | |
200 Stonecrest Blvd, Smyrna, TN 37167-6810 | |
(615) 768-2000 | |
(615) 768-2707 |
Full Name | Olumide Ibrahim Anifowoshe |
---|---|
Gender | Male |
Speciality | Hospitalist |
Location | 200 Stonecrest Blvd, Smyrna, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972558286 | NPI | - | NPPES |
38892822 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 37852 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Olumide Ibrahim Anifowoshe, MD 200 Stonecrest Blvd, Smyrna, TN 37167-6810 Ph: (615) 768-2000 | Olumide Ibrahim Anifowoshe, MD 200 Stonecrest Blvd, Smyrna, TN 37167-6810 Ph: (615) 768-2000 |
News Archive
Officials in California, Maryland, Illinois, Kansas and Georgia give status checks on their online health insurance exchanges. In the meantime, officials in Oregon are pressuring their website contractor, Oracle, to speed up fixes to the marketplace as insurers consider extending deadlines there.
Fred Hutchinson Cancer Research Center, The Netherlands Cancer Institute (NKI) and Cancer Research Technology Limited (CRT) today have released details of the development and commercialisation of a powerful protein-genome interaction mapping technology termed 'DamID.'
Boehringer Ingelheim Pharma GmbH & Co. KG, an international research-driven pharma company, and Eurofins Medigenomix GmbH, a competence center for genetic analyses of the Eurofins Scientific Group, concluded a long-term service agreement in the area of DNA banking, as well as a master service agreement for pharmacogenetic and pharmacogenomic services. For DNA banking Eurofins Medigenomix is supporting operations of Boehringer Ingelheim's central DNA bank at Biberach an der Riss.
Positron Corporation a molecular imaging company announced today that it is developing indium oxine, a radiopharmaceutical widely used for the radiolabeling of blood elements. This project signifies Positron's entrance into direct radiopharmaceutical manufacturing and sales; indium oxine is the first new product in development at Positron's research, development and manufacturing facility in Crown Point, Indiana.
› Verified 5 days ago